Contract research and development in the pharmaceutical sector is a critical activity for many multinational enterprises. The safe harbour regime under the Income Tax Act, 2025 provides a clear benchmark for determining the arm's length margin for such services: 24% operating profit margin. Understanding this provision is essential for pharmaceutical companies with contract R&D arrangements.
The Regulatory Framework
Rule 89 of the Income Tax Rules, 2026 prescribes the safe harbour for contract research and development services wholly or partly relating to generic pharmaceutical drugs. The operating profit margin declared by the eligible assessee from the eligible international transaction in relation to operating expense incurred must be not less than 24%.
Scope of the Safe Harbour
Eligible Services
The safe harbour applies to contract research and development services wholly or partly relating to generic pharmaceutical drugs.
Revenue Cap
The 24% margin applies where the aggregate operating revenue of such transaction does not exceed a sum of ₹300 crore.
"Insignificant Risk" Requirement
To avail the safe harbour, the assessee must operate with insignificant risk. This is determined based on:
-
Functional Profile: The foreign principal performs most economically significant functions including conceptualisation, design, and strategic direction
-
Funding: The foreign principal provides funds, capital, and economically significant assets including intangibles required for research or product development
-
Supervision: The assessee works under direct supervision of the foreign principal which controls or supervises research or product development
-
Risk Profile: The assessee does not assume economically significant realised risks
-
Ownership: The assessee has no ownership right on the outcome of the research, which vests with the foreign principal
The 24% Margin
What It Means
The operating profit margin of 24% is the minimum margin that must be declared by the eligible assessee from the eligible international transaction in relation to operating expense incurred. If the declared margin is 24% or higher, the transfer price will be accepted without further scrutiny.
Historical Context
The 24% margin represents a reduction from the earlier prevailing 29% and 30% margin rates. The reduction reflects the evolving nature of the pharmaceutical R&D landscape and the increasing commoditisation of certain R&D services.
Definition of Operating Profit Margin
Operating profit margin in relation to operating expense means the ratio of operating profit, being the operating revenue in excess of operating expense, to the operating expense expressed in terms of percentage.
Operating Expense
Operating expense includes:
- Costs incurred in the tax year in relation to the international transaction during the course of normal operations
- Costs relating to Employee Stock Option Plan or similar stock-based compensation provided for by associated enterprises
- Reimbursement to associated enterprises of expenses incurred at cost
- Amounts recovered from associated enterprises on account of expenses incurred
- Depreciation and amortisation expenses
Operating expense does not include:
- Interest expense
- Provision for unascertained liabilities
- Pre-operating expenses
- Loss arising on account of foreign currency fluctuations
- Extraordinary expenses
- Loss on transfer of assets or investments
- Expense on account of income-tax
- Other expenses not relating to normal operations
Operating Revenue
Operating revenue does not include:
- Interest income
- Income arising on account of foreign currency fluctuations
- Income on transfer of assets or investments
- Refunds relating to income-tax
- Provisions written back
- Extraordinary incomes
- Other incomes not relating to normal operations
Certification Requirements
The safe harbour for contract R&D requires certification by an accountant confirming:
- The operating profit margin declared is not less than 24%
- The insignificant risk conditions are satisfied
- The aggregate operating revenue does not exceed ₹300 crore
Expert Legal Guidance
Understanding the 24% safe harbour margin for pharma contract R&D is essential for pharmaceutical companies. Anuj Desai & Associates provides expert advisory services on transfer pricing compliance, helping taxpayers assess eligibility, calculate operating margins, and ensure compliance with all safe harbour conditions.